Positron Emission Tomography (FDG) for Brain, Cervical, Ovarian, Pancreatic, Small Cell Lung, and Testicular Cancers
This national coverage determination (NCD) was issued on January 28, 2004. The NCD contains a 4-part framework of diagnosis, staging, restaging and monitoring response to treatment for specific cancers. For all FDG PET indications for which CMS has a noncoverage determination, the NCD determined that the study is reasonable and necessary when the provider is participating in and patients are enrolled in a clinical research study designed to collect information at the time of service to assist in patient management.
The clinical research study must insure that:
- Specific hypotheses are identified prospectively;
- Hospitals and providers are qualified to provide the FDG PET scan and interpret the results;
- Participating hospitals and providers report specific data elements on enrolled patients
Decision Memorandum: http://www.cms.gov/medicare-coverage-database/details/nca-decision-memo.aspx?NCAId=92
On its website, CMS will maintain a list of all approved studies and facility locations. There are approximately 2200 facilities participating in the clinical research study. A list of facility locations can be found here: http://www.cms.gov/MedicareApprovedFacilitie/NOPR/list.asp#TopOfPage\
Study Title: The National Oncologic PET Registry (NOPR)
Clinical Trials.gov identifier: NCT00868582 (Recruiting)
http://www.clinicaltrials.gov/ct2/show/NCT00868582?term=PET+Academy+of+Molecular+Imaging&rank=2
See Positron Emission Tomography (FDG) for Solid Tumors (CAG-00181R)
- Page last Modified: 06/19/2012 8:35 AM
- Help with File Formats and Plug-Ins